[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced on 05 September 2025 that it purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. After settlement the company's registered share capital is 8,955,614,051 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,951,733,846 ordinary shares with voting rights. A full breakdown of individual trades is available at the provided RNS link and on the company website. The announcement states it does not constitute an offer or solicitation in any jurisdiction.

Positive

• Buyback execution completed under the previously announced programme, showing follow-through on capital allocation plans
• Updated voting share count clearly provided (8,951,733,846), helping shareholders determine disclosure obligations

Negative

• No financial impact details provided (cash spent, price-weighted averages or effect on EPS not disclosed in this notice)

Insights

Corporate Governance Expert

TL;DR: Share cancellation reduces outstanding shares slightly and updates the voting share count for regulatory disclosure.

The filing documents a routine tranche of a previously announced buyback and cancellation. The cancellation of 353,360 shares is explicitly recorded and the resulting registered and voting share counts are provided for shareholders to assess disclosure thresholds under FCA rules. The company also provides the regulatory trade breakdown link, satisfying transparency requirements under the Market Abuse Regulation as applied in the UK.

Financial Analyst

TL;DR: Small-scale buyback tranche completed; impact on per-share metrics is likely immaterial given the large share base.

The disclosed transaction size (353,360 shares) and the updated totals (8,955,614,051 registered; 8,951,733,846 voting shares) are clear and precise. The filing contains no earnings, debt, or cash impact figures, so material financial effects cannot be quantified from this notice alone. The company directs readers to an individual trade breakdown for transaction-level detail.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	05 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

05 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 353,360 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	04 September 2025	04 September 2025	04 September 2025
Number of Shares purchased:	353,360	-	-
Highest price paid per Share (p):	373.1000	-	-
Lowest price paid per Share (p):	368.6000	-	-
Volume weighted average price paid per Share (p):	370.4013	-	-

Following the settlement of the above, the Company's registered share capital is 8,955,614,051 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,951,733,846 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/1131Y_1-2025-9-4.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 05, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLN) purchase on 04 September 2025?

The company purchased and cancelled 353,360 ordinary shares of £0.01 each under the second tranche of its share buyback programme.

How many Haleon shares are outstanding with voting rights after this transaction?

After settlement there are 8,951,733,846 ordinary shares with voting rights.

Where can I find the full breakdown of individual trades for this buyback?

A full breakdown is available at the RNS link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/1131Y_1-2025-9-4.pdf and on the company's investors website.

Does this announcement include the cash amount spent on the share purchases?

No. The filing does not state the total cash spent or the weighted average price; only the number of shares purchased is disclosed.

Is this announcement an offer or solicitation for securities?

No. The announcement explicitly states it does not constitute an offer or solicitation for securities in any jurisdiction.